Moteur de recherche d’entreprises européennes

Financement de l’UE (9 999 253 €) : Un jumeau virtuogène d’immunothérapie CEllulaR pour un traitement personnalisé du cancerNT Hor 01/12/2023 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Un jumeau virtuogène d’immunothérapie CEllulaR pour un traitement personnalisé du cancerNT

"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy. The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem. To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process. Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."


F. Hoffmann-LA Roche AG ?
Charite - Universitaetsmedizin Berlin 166 730 €
Collaborate Project Management GmbH 233 423 €
European Society FOR Blood AND Marrow Transplantation 1 071 585 €
Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. 2 429 610 €
Healthtree Foundation Inc. 668 430 €
Helmholtz-Zentrum Dresden-Rossendorf e. V. 280 828 €
Information Technology FOR Translational Medicine (Ittm) SA 632 384 €
Institut Curie 435 643 €
Masarykova Univerzita 564 221 €
Myeloma Patients Europe Aisbl 101 994 €
Singleron Biotechnologies GmbH 571 646 €
Trinetx Oncology GmbH 100 038 €
Universitaet Leipzig 1 715 059 €
Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat 157 404 €
Universitair Medisch Centrum Utrecht 465 986 €
Universite de Namur 404 274 €

https://cordis.europa.eu/project/id/101136379

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : F. Hoffmann-La Roche SA, Bâle, Suisse.